Equity Profile

ASND

Ascendis Pharma A/S

Health CareBiotechnology$17.4B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Ascendis Pharma A/S is a biotechnology company focused on developing innovative therapies for rare diseases and endocrine disorders. Operating in the health care sector, it aims to address unmet medical needs through its unique drug development platform.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ASND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+528.60%

Avg Stock Reaction

+0.76%

Last Quarter Recap

In Q1-2026, Ascendis Pharma reported a surprising EPS of $11.46, significantly exceeding expectations. The stock reacted positively, gaining 4.34% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Ascendis Pharma's upcoming earnings are uncertain due to the lack of analyst estimates and management guidance. Investors will be keenly watching for any updates on product development and financial performance.

Bull Case

The bull case hinges on continued strong performance in EPS and revenue, suggesting that the company is effectively advancing its product pipeline and gaining market traction.

Bear Case

The bear case centers on the potential for disappointing revenue or increased R&D costs, which could signal challenges in product development or market acceptance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2-2026?

Given the company's recent EPS surprise, this figure will be crucial in determining market sentiment and stock performance.

How are R&D expenses expected to impact future revenue?

Investors will be looking for clarity on how R&D spending aligns with product development timelines and potential revenue generation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Ascendis Pharma to leverage its recent EPS surprise as a springboard for continued growth.

Supporting Evidence

The recent EPS surprise of +5278.54% indicates strong operational performance that may not be fully reflected in current market expectations.

Options pricing suggests a significant move is anticipated, which could indicate that traders believe in potential upside.

Key Risk

If the EPS comes in significantly above expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently uncertain about Ascendis Pharma's ability to maintain its recent performance, making these thresholds critical.

Bull Confirmed If

A reported EPS significantly above $11.46 would confirm strong financial health and market confidence.

Bear Confirmed If

An EPS below $0.21 would indicate potential issues in profitability and market acceptance.

Pre-Earnings Positioning

Options Market

Implied Move

±9.25%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±9.3% while ASND has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

41.3%

Calls (3K)P/C Ratio: 5.70Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ascendis Pharma beats expectations, history suggests a potential stock increase of around +4.71%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management commentary.

Miss

Should the company miss expectations, history indicates a potential decline of around -1.60%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and timelines.
2Details on R&D expenditures and their expected impact on future revenue.
3Management's outlook on market conditions and competitive landscape.
4Insights into customer feedback or market reception of existing products.
5Any commentary on strategic partnerships or collaborations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ASND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+528.60%

Avg Stock Reaction

+0.76%

Last Quarter Recap

In Q1-2026, Ascendis Pharma reported a surprising EPS of $11.46, significantly exceeding expectations. The stock reacted positively, gaining 4.34% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

The bull case hinges on continued strong performance in EPS and revenue, suggesting that the company is effectively advancing its product pipeline and gaining market traction.

Bear Case

The bear case centers on the potential for disappointing revenue or increased R&D costs, which could signal challenges in product development or market acceptance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2-2026?

Given the company's recent EPS surprise, this figure will be crucial in determining market sentiment and stock performance.

How are R&D expenses expected to impact future revenue?

Investors will be looking for clarity on how R&D spending aligns with product development timelines and potential revenue generation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Ascendis Pharma to leverage its recent EPS surprise as a springboard for continued growth.

Supporting Evidence

The recent EPS surprise of +5278.54% indicates strong operational performance that may not be fully reflected in current market expectations.

Options pricing suggests a significant move is anticipated, which could indicate that traders believe in potential upside.

Key Risk

If the EPS comes in significantly above expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently uncertain about Ascendis Pharma's ability to maintain its recent performance, making these thresholds critical.

Bull Confirmed If

A reported EPS significantly above $11.46 would confirm strong financial health and market confidence.

Bear Confirmed If

An EPS below $0.21 would indicate potential issues in profitability and market acceptance.

Pre-Earnings Positioning

Options Market

Implied Move

±9.25%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±9.3% while ASND has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

41.3%

Calls (3K)P/C Ratio: 5.70Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ascendis Pharma beats expectations, history suggests a potential stock increase of around +4.71%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management commentary.

Miss

Should the company miss expectations, history indicates a potential decline of around -1.60%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and timelines.
2Details on R&D expenditures and their expected impact on future revenue.
3Management's outlook on market conditions and competitive landscape.
4Insights into customer feedback or market reception of existing products.
5Any commentary on strategic partnerships or collaborations.